<?xml version="1.0" encoding="UTF-8"?>
<fig id="Fig4">
 <label>Fig. 4</label>
 <caption>
  <p>Targeted immunosuppressive therapy for COVID-19: Macrophages play a significant role in cytokine release syndrome associated with SARS-CoV-2 infection. The cells get activated directly by viruses as well as bystander activation with autocrine and paracrine actions of the proinflammatory cytokines mainly derived from the macrophages, NK cells, and T cells. The target of immunosuppressive therapy is denoted by the numbered boxes as described below. The red color box denotes the drugs for which clinical trials are ongoing and the grey color box denotes the drugs for which there is no ongoing clinical trial registered at present for the treatment of COVID-19. (1) TLR7 mediated viral signaling at the endosomal level—&gt; chloroquine and hydroxychloroquine. (2) TLR4-TRIF signaling—&gt; plausible therapeutic target, no approved drug. (3) IRAK4 inhibitor—&gt; PF-06650833, CA-4948. (4) (a) Anti IL-1β—&gt; canakinumab, (b) IL-1 receptor antagonist- &gt; anakinra. (5) TNF inhibitors—&gt; infliximab, adalimumab, etanercept. (6) GM-CSF signaling inhibition—&gt; lenzilumab. (7) (a) Anti IL-6—&gt; siltuximab, clazakizumab (b) Anti IL-6 receptor &gt; tocilizumab, sarilumab. (8) Anti IFN γ—&gt; emapalumab. (9) JAK inhibitor—&gt; baricitinib, ruxolitinib, tofacitinib (multi-cytokine targeted therapy). 
   <italic>CCL2</italic> chemokine (C–C motif) ligand 2, 
   <italic>CXCL8</italic> C-X-C motif chemokine ligand 8, 
   <italic>ACE2</italic> angiotensin-converting enzyme 2, 
   <italic>GM-CSF</italic> granulocyte–macrophage colony-stimulating factor, 
   <italic>IFN</italic> interferon, 
   <italic>IL</italic> interleukin, 
   <italic>IRAK4</italic> interleukin-1 receptor-associated kinase 4, 
   <italic>IRF</italic> interferon regulatory transcription factor, 
   <italic>ISRE</italic> interferon-stimulated response element, 
   <italic>JAK</italic> Janus kinase, 
   <italic>MDA-5</italic> melanoma differentiation-associated protein-5, 
   <italic>MVAS</italic> mitochondrial antiviral-signaling protein, 
   <italic>MYD88</italic> myeloid differentiation primary response-88, 
   <italic>RIG-1</italic> retinoic acid-inducible gene-I, 
   <italic>NF-κB</italic> nuclear factor kappa-light-chain-enhancer of activated B cells, 
   <italic>STAT</italic> signal transducer and activator of transcription, 
   <italic>TLR</italic> toll-like receptor, 
   <italic>TNF</italic> tumor necrosis factor
  </p>
 </caption>
 <graphic xlink:href="296_2020_4639_Fig4_HTML" id="MO4" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
